The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain

Abstract

The central nervous system (CNS) is the final frontier in drug delivery because of the blood–brain barrier (BBB), which poses significant barriers to the access of most drugs to their targets. Kynurenic acid (KYNA), a tryptophan (Trp) metabolite, plays an important role in behavioral functions, and abnormal KYNA levels have been observed in neuropsychiatric conditions. The current challenge lies in delivering KYNA to the CNS owing to its polar side chain. Recently, C-3 side chain-modified KYNA analogs have been shown to cross the BBB; however, it is unclear whether they retain the biological functions of the parent molecule. This study examined the impact of KYNA analogs, specifically, SZR-72, SZR-104, and the newly developed SZRG-21, on behavior. The analogs were administered intracerebroventricularly (i.c.v.), and their effects on the motor domain were compared with those of KYNA. Specifically, open-field (OF) and rotarod (RR) tests were employed to assess motor activity and skills. SZR-104 increased horizontal exploratory activity in the OF test at a dose of 0.04 μmol/4 μL, while SZR-72 decreased vertical activity at doses of 0.04 and 0.1 μmol/4 μL. In the RR test, however, neither KYNA nor its analogs showed any significant differences in motor skills at either dose. Side chain modification affects affective motor performance and exploratory behavior, as the results show for the first time. In this study, we showed that KYNA analogs alter emotional components such as motor-associated curiosity and emotions. Consequently, drug design necessitates the development of precise strategies to traverse the BBB while paying close attention to modifications in their effects on behavior.

Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer’s Dementia: Clinical Trial Systematic Review

“…Hence, alternative treatments may improve patients' quality of life with AD. Novel therapeutic opportunities for AD strategies include improving cognitive function and reducing amyloid deposition, opening up new treatment options, and including monoclonal antibodies [6,[19][20][21][22][23][24][25]. Traditionally, AD has been treated with drugs that relieve symptoms, such a cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and N-methyl-D aspartate receptor (NMDAR) antagonists (memantine).…”

“…Hence, alternative treatments may improve patients’ quality of life with AD. Novel therapeutic opportunities for AD strategies include improving cognitive function and reducing amyloid deposition, opening up new treatment options, and including monoclonal antibodies [ 6 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”

A Decade of Dedication: Pioneering Perspectives on Neurological Diseases and Mental Illnesses

“…This entails investigating how these changes affect cognitive functions such as memory and decision-making, as well as their implications for cognitive development and disorders [15][16][17][18][19][20][21]. Hence, we may be able to uncover the complex mechanisms that underpin neurodegenerative disorders and investigate potential therapeutic strategies that hold promise for novel treatments [22][23][24][25][26][27][28].…”

Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry

“…Translational research in neurological and psychiatric diseases is a rapidly advancing field that promises to redefine our approach to these complex conditions [1][2][3][4][5][6][7][8][9]. The Topic "Emerging Translational Research in Neurological and Psychiatric Diseases" is a testament to this evolution, showcasing 22 pioneering papers that span a diverse range of topics and methodologies.…”